ATTR cardiac amyloidosis

Article written and reviewed by Dr Luca Moretti

ATTR cardiac amyloidosis is a cardiomyopathy caused by accumulation in the heart of fibrils derived from transthyretin. The protein, produced almost entirely by the liver, circulates as a tetramer; its dissociation promotes misfolded monomers, oligomers and extracellular fibrils. Deposition stiffens the myocardium, reduces cardiac output, involves the atria and conduction system and leads to heart failure. ATTR cardiomyopathy is therefore a systemic proteotoxic disease, not simply hypertrophy of aging.

The wild-type form, ATTRwt, derives from transthyretin with a normal sequence that becomes amyloidogenic mainly with age and is diagnosed predominantly in older men. The variant form, ATTRv, is caused by a pathogenic germline TTR variant and generally follows autosomal dominant inheritance, with cardiac, neuropathic or mixed phenotypes. The wild-type versus variant distinction requires genetic testing after disease confirmation because age and apparent absence of family history are not reliable discriminators.

ATTR-CM was long underdiagnosed and identified only at an advanced stage or at autopsy. Bone scintigraphy and the availability of therapies have revealed cases among patients with heart failure with preserved ejection fraction, aortic stenosis, thickened walls and conduction disease. Frequencies in studies, however, depend on selection criteria and are not equivalent to population prevalence. Targeted case finding is appropriate when a combination of red flags increases pre-test probability.

The diagnosis must always exclude AL before a nonbiopsy pathway is used. Monoclonal gammopathy is common in older people and may coexist with ATTR, while some AL cases show scintigraphic uptake; classifying a patient by age or tracer alone can delay urgent hematologic therapy. Algorithm safety depends on complete monoclonal-protein testing and correct myocardial localization of uptake.

ATTR wild-type and variant ATTR

ATTRwt mainly affects the heart and musculoskeletal tissues. Prevalence increases with age, but anatomic transthyretin deposition does not always equate to clinical cardiomyopathy; evidence of organ involvement is required. The marked male predominance in cohorts may reflect biology, diagnostic thresholds and referral patterns, while women may be recognized later or with lower wall thickness. Age-related penetrance in the wild-type form is not a Mendelian concept but a probability of deposition and disease that increases over time.

ATTRv includes more than one hundred amyloidogenic variants with different geographic distributions and phenotypes. p.Val50Met, historically Val30Met, is often neuropathic in endemic areas but may involve the heart with late onset; p.Val142Ile, historically Val122Ile, is frequent among people of African ancestry and is associated mainly with late-onset cardiomyopathy. Updated nomenclature should be accompanied by the historical name to avoid errors in records and among relatives.

Penetrance and severity of ATTRv depend on variant, age, sex, geographic origin and possibly the inherited allele, making it impossible to predict the course from the genetic result alone. A p.Val142Ile carrier is not a patient with cardiomyopathy until organ involvement exists, and a relative who tests negative has not inherited that familial risk. The carrier-disease distinction is essential to avoid premature diagnosis without a phenotype.

ATTRv neuropathy is length-dependent and progressive, with pain, sensory loss, weakness and dysautonomia; gastrointestinal disorders, orthostatic hypotension, erectile dysfunction and weight loss may occur. The eye and leptomeninges may be involved in specific variants because transthyretin is also produced locally. Neurologic assessment should be performed even when the initial presentation is cardiac because it determines treatment and quality of life.

ATTRwt is diagnosed when cardiac ATTR is demonstrated and sequencing does not identify a pathogenic TTR variant. It is not an inherited disease in the Mendelian sense and does not justify cascade testing in children, although relatives retain general cardiovascular risk related to age and comorbidities. Family communication prevents the word amyloidosis from being automatically interpreted as genetic transmission.

Preclinical clues and cardiac manifestations

Bilateral carpal tunnel syndrome may precede cardiomyopathy by five to ten years, as may lumbar stenosis, trigger finger, joint replacement and atraumatic biceps tendon rupture. Tenosynovial tissue obtained at surgery may contain amyloid, but positivity alone does not establish the degree of cardiac involvement. The musculoskeletal phase creates a window for recognition provided that clues are linked to age and cardiac signs.

Heart failure presents with dyspnea, edema, ascites and reduced functional capacity, often with preserved ejection fraction but low stroke volume. Blood pressure may decline over time and antihypertensive drugs become less well tolerated. With progression, right ventricular function and left ventricular ejection fraction decline while diuretic requirements increase. Progressive low output explains fatigue and frailty that are not proportional to congestion alone.

Atrial fibrillation is very common in ATTRwt and may be present at diagnosis. Atrial deposition reduces contraction and emptying velocity, promoting thrombi even during anticoagulation or sinus rhythm; functional mitral and tricuspid regurgitation amplify congestion. Amyloid atrial disease requires a low threshold for transesophageal imaging before cardioversion, even when the arrhythmia appears short-lived.

Atrioventricular block, sinus-node disease and bundle-branch block may precede heart failure. A pacemaker implanted years earlier in an older person with subsequent wall thickening is a retrospective red flag; a high percentage of right ventricular pacing may worsen dyssynchrony and function. The electrical history should be reconstructed using previous ECGs and device interrogation rather than limited to the current tracing.

Calcific aortic stenosis and ATTR coexist in some older patients, especially in TAVI pathways. Low flow, thickened walls and reduced reserve may derive from either condition, and the presence of amyloid modifies the picture but does not automatically make intervention futile. Valvular overlap requires multidisciplinary assessment of frailty, attributable symptoms and expected benefit.

Nonbiopsy diagnosis and conditions that invalidate it

The pathway begins with serum immunofixation, urine immunofixation and free light chains. If all are negative, grade 2 or 3 myocardial uptake on scintigraphy with 99mTc-DPD, PYP or HMDP, confirmed by SPECT in a compatible phenotype, has sufficient specificity for cardiac ATTR without biopsy. The Gillmore criterion does not include electrophoresis alone and cannot be applied if any of the three monoclonal components is abnormal.

Planar assessment compares cardiac and bone uptake, but SPECT or SPECT/CT distinguishes true myocardial activity from blood pool, ribs, calcified valves or overlap. Timing varies with tracer and local protocols; the quantitative heart-to-contralateral ratio may support but not replace visual and tomographic assessment. Three-dimensional localization is essential to avoid false positives in patients with low output and slow clearance.

Grade 1 uptake is indeterminate and requires CMR, follow-up or biopsy according to probability; a grade 0 study does not exclude some ATTR variants, including specific substitutions with low avidity, or very early disease. Recent infarction, hydroxychloroquine exposure and rare amyloid types are additional pitfalls. A negative scintigraphy lowers probability in a context-dependent manner but does not override genetics, biopsy or a strongly discordant phenotype.

If a monoclonal component is present, positive uptake does not distinguish ATTR with MGUS from AL. Amyloid must be demonstrated and typed by mass spectrometry or a validated method; a positive and typed fat-pad biopsy may suffice if cardiac involvement is clearly coherent, otherwise endomyocardial biopsy provides the most direct link. Tissue typing protects the patient from a false ATTR diagnosis while an AL clone continues producing toxic light chains.

CMR demonstrates infiltration and quantifies ECV but does not replace the biochemical-scintigraphic pathway. It is particularly useful with equivocal scintigraphy, suspected alternative cardiomyopathy or a need to assess tissue and function; echocardiography with strain establishes severity and follow-up. Multimodality convergence increases certainty and recognizes phenocopies such as HCM, Fabry disease, hypertension and iron overload.

TTR genetics and screening of relatives

After an ATTR diagnosis, TTR sequencing is offered to every patient with counseling. Restricting testing to younger or neuropathic patients would miss late-onset cardiac variants; p.Val142Ile may present in the eighth decade and a family may be unaware of previous diagnoses. Universal etiologic testing distinguishes the hereditary form and changes information for children, neurologic assessment and sometimes therapeutic choice.

A pathogenic or likely pathogenic variant confirms ATTRv in a patient with ATTR deposition. A variant of uncertain significance must not be used to predict disease in relatives and requires correlation with phenotype, frequency, literature and segregation. Demonstrated ATTR deposition does not automatically make every rare TTR variant found in the same individual causal.

At-risk adult relatives may choose targeted testing after counseling, understanding incomplete penetrance, the absence of an exact age of onset and psychological and reproductive implications. Testing in minors is generally deferred when there is no medical benefit in childhood, except for variants and specialist programs with specific reasons. Predictive timing seeks to begin surveillance before disease without turning decades of life into unnecessary monitoring.

Carriers undergo clinical, neurologic, ECG, biomarker and imaging assessments at intervals adapted to the variant, family history and expected age of onset. Scintigraphy may be introduced when biomarkers or imaging suggest deposition, but there is no single universally validated schedule. Personalized surveillance distinguishes signs of involvement from common comorbidities and defines when a carrier becomes a candidate for therapy.

Staging and measurement of progression

The National Amyloidosis Centre system divides cardiac ATTR using NT-proBNP of 3000 ng/L and eGFR of 45 mL/min/1.73 m²: no adverse value defines stage I, one defines stage II and both define stage III. The scheme stratifies survival in cohorts, but NT-proBNP is influenced by atrial fibrillation and volume status and eGFR by age and comorbidities. The NAC class is a prognostic framework, not an automatic criterion for treatment access or exclusion.

NYHA class, six-minute walk distance, quality of life, hospitalizations, diuretic dose, troponin, right ventricular function and strain complete severity assessment. Cardiopulmonary exercise testing can quantify peak oxygen uptake and ventilatory inefficiency in patients able to exercise. Measured function captures an impact that mass and ejection fraction may underestimate.

ECV on CMR and quantitative nuclear uptake are promising for measuring burden but do not yet constitute universal surrogates for changing therapy in every patient. Technical differences, scanners and intervals make use of the same center and protocol important. Tissue progression should be interpreted together with clinical findings and biomarkers, avoiding frequent serial tests without decision consequences.

An increase in NT-proBNP may reflect congestion, atrial fibrillation or renal failure and should be confirmed after stabilization. Conversely, biomarker stability in a patient with functional decline and increasing diuretic dose does not guarantee control. The composite trajectory is more robust than a single number and helps distinguish slow response from true failure.

Transthyretin stabilizers and silencers

Tafamidis binds to thyroxine-binding sites and stabilizes the tetramer, reducing dissociation. In ATTR-ACT it reduced all-cause mortality and cardiovascular hospitalizations and slowed decline in walking ability and quality of life compared with placebo; clinical separation takes time and benefit is greater when disease is not terminal. Stabilization with tafamidis does not immediately dissolve fibrils and must continue alongside active heart failure management.

Acoramidis is a high-affinity stabilizer designed to mimic the protective effect of a nonamyloidogenic TTR variant. In ATTRibute-CM it improved a hierarchical endpoint including mortality, hospitalizations, NT-proBNP and walking distance; it is authorized in the European Union for adult wild-type or variant ATTR-CM. Evidence for acoramidis demonstrates efficacy versus placebo, not direct superiority over tafamidis.

Vutrisiran is a GalNAc-conjugated small interfering RNA that reduces hepatic TTR mRNA and therefore production of both wild-type and variant protein. In HELIOS-B it reduced a composite of mortality and recurrent cardiovascular events and slowed functional decline; the European indication includes adults with ATTR-CM. Suppression of synthesis requires vitamin A supplementation according to the prescribing information and attention to pregnancy, ocular issues and other safety aspects.

Patisiran improved functional capacity and quality of life in APOLLO-B, but regulatory indications and availability differ and it should not automatically be equated with drugs authorized for ATTR-CM. Other silencers, clearance antibodies and gene-editing approaches are in development. The evidence-authorization distinction prevents an experimental result from being presented as clinical standard before regulatory evaluation.

There are no robust head-to-head comparisons among tafamidis, acoramidis and vutrisiran, nor sufficient evidence for routine combination of a stabilizer and a silencer. Differences in populations, endpoints and background therapy make it incorrect to rank drugs by comparing percentages across trials. Individual choice considers indication, stage, neuropathy, comorbidities, route of administration, interactions, access and preferences through an expert center.

Neuropathy, dysautonomia and musculoskeletal signs

In ATTRv, small-fiber injury causes burning pain, altered thermal sensation and dysautonomia, while large-fiber involvement causes loss of proprioception, weakness and instability. Progression may be asymmetric at onset and confused with diabetes, radiculopathy or compression syndromes. A structured neurologic examination includes strength, reflexes, sensation, gait and autonomy, not merely a generic question about tingling.

Orthostatic hypotension, gastrointestinal disorders, neurogenic bladder, erectile dysfunction and altered sweating indicate dysautonomia. Diuretics needed for congestion can worsen it, whereas indiscriminate sodium and fluid expansion aggravates heart failure; stockings, physical maneuvers and pressor drugs are adapted to the cardiac balance. The tension between volume and orthostasis requires supine and standing measurements and gradual adjustments.

Bilateral carpal tunnel syndrome, lumbar spinal stenosis, biceps tendon rupture and amyloid deposition in tissue obtained during joint replacement may precede ATTR-CM by many years, especially wild-type disease. They are enrichment markers rather than diagnostic tests: many older people have them without cardiac amyloidosis. The orthopedic chronology becomes useful when associated with thickened walls, heart failure, arrhythmias or unexplained biomarkers.

Sarcopenia and weight loss result from low output, intestinal congestion, reduced activity and neuropathy and worsen tolerance and prognosis. Nutritional assessment should avoid both excess sodium and restrictions that further reduce calories and protein. Functional reserve is a clinical target: individualized rehabilitation and fall prevention complement TTR-specific therapy.

How to interpret therapeutic trials

ATTR-ACT compared tafamidis with placebo in selected patients and demonstrated reduced mortality and cardiovascular hospitalizations in the hierarchical analysis, along with slower decline in walking distance and quality of life. Mortality curves separated after an interval, consistent with a treatment that slows new fibril formation rather than immediately correcting hemodynamics. The delayed benefit reinforces the importance of starting before terminal-stage disease.

ATTRibute-CM evaluated acoramidis with a hierarchical endpoint integrating mortality, cardiovascular events, NT-proBNP and walking distance. HELIOS-B evaluated vutrisiran on mortality and recurrent cardiovascular events, including a contemporary population in which a proportion received stabilizers. Endpoints, duration and background treatment differed, so indirect comparison of percentage reductions cannot establish a reliable ranking.

Registration trials often exclude or underrepresent patients with extreme hypotension, very advanced renal failure, severe frailty or functional class IV. Applying results requires checking how closely the real patient resembles the studied population and whether life expectancy allows time for benefit to emerge. Transferability of evidence is an explicit clinical assessment, not an automatic reason to deny treatment to an older person.

Total mortality, recurrent hospitalizations, walking distance, questionnaires and biomarkers describe different dimensions. A hierarchical composite endpoint assigns priority and compares each pair according to a predefined order; it is not equivalent to a simple sum of events and does not allow the same weight to be assigned to every component. Reading the endpoint protects against promotional interpretations and supports proportionate communication of benefit.

Aortic stenosis, kidney disease and frailty

ATTR is found in a clinically relevant proportion of older adults assessed for severe aortic stenosis. Low flow, thickened walls, right ventricular dysfunction, carpal tunnel syndrome and disproportion between symptoms and gradient increase suspicion, but diagnosis still follows the monoclonal-scintigraphic algorithm. Valvular coexistence does not make TAVI futile: it requires an individual estimate of frailty, reserve and the proportion of symptoms that can be corrected.

Kidney disease raises NT-proBNP, limits diuretics and contrast agents and can make staging more complex. It does not, however, invalidate immunofixation and scintigraphy when interpreted correctly; polyclonal light chains rise with reduced filtration, whereas true monoclonality requires the full panel. ATTR nephrocardiology distinguishes analytical interference, congestion and independent kidney disease.

Frailty is not the same as chronological age. Walking speed, strength, activities of daily living, cognition, nutrition and social support predict tolerance of procedures and ability to adhere to prolonged therapies. The geriatric profile can identify reversible deficits and makes decision-making fairer than a rigid age threshold.

In patients with very advanced disease, the question is not only whether a drug is biologically active, but whether it can provide a perceptible benefit in the time available. Palliative care, treatment of dyspnea, advance planning and home care can coexist with disease-specific therapy when goals are aligned. Therapeutic proportionality avoids both premature abandonment and interventions without concrete usefulness.

Cardiac treatment and advanced situations

Loop diuretics are the cornerstone of congestion management and may be combined with mineralocorticoid receptor antagonists or other diuretics in resistant cases, while monitoring hypotension and hypoperfusion. Dysautonomia, nephropathy and low stroke volume make the balance delicate; in some ATTRv cases midodrine may be considered for orthostatic hypotension under supervision. Volume management aims at quality of life and perfusion rather than predefined doses.

Standard heart failure drugs are adapted. Observational data suggest that mineralocorticoid receptor antagonists are often tolerated and that low-dose beta-blockers may be useful with specifically reduced ejection fraction, while ACE inhibitors and ARBs frequently cause hypotension; SGLT2 inhibitors have growing observational data but no dedicated ATTR trials. Nonrandomized evidence can guide caution and selection but is not equivalent to a universal recommendation.

Atrial fibrillation is anticoagulated regardless of the CHA2DS2-VASc score according to major consensus documents unless contraindicated, and cardioversion requires transesophageal imaging because of the high prevalence of thrombi. Amiodarone is often used for rhythm control; ablation and invasive strategies have variable results and higher recurrence in advanced stages. Thromboembolic priority accompanies every rhythm decision.

A pacemaker is indicated for bradyarrhythmias and conduction disorders meeting usual pacing criteria, but a high percentage of right ventricular pacing can impair function; more physiologic pacing or CRT is considered case by case. Primary-prevention ICD benefit has not been clearly demonstrated for all patients, whereas secondary prevention is considered if prognosis and event mechanism allow. Electrical therapy must recognize that many deaths in advanced disease are not shockable tachyarrhythmias.

Heart transplantation is possible in selected patients, especially younger individuals, without incompatible neuropathy or frailty. The role of liver transplantation in ATTRv has declined with silencers and it does not eliminate extrahepatic production or wild-type deposition on pre-existing material; specific variants and contexts require dedicated assessment. Advanced therapy integrates organs, gene and drug availability without automatically applying historical strategies.

Follow-up, family and realistic goals

Follow-up records functional class, weight, orthostatic blood pressure, diuretic dose, hospitalizations, rhythm, device status, NT-proBNP, troponin, eGFR and echocardiography. In ATTRv it adds strength, sensation, gait, autonomy and dysautonomia; ocular and nutritional assessments follow the phenotype and drug. Multisystem measurement prevents a stable heart from concealing progressive neuropathy or vice versa.

Response to therapy is often stabilization or slowing rather than rapid improvement. A patient may continue to require more diuretic while the drug reduces the rate of worsening compared with natural history; conversely, apparent short-term stability does not prove individual efficacy. Temporal assessment accounts for biologic delay and does not stop or combine therapies on the basis of isolated fluctuations.

In familial carriers, surveillance seeks the first objective sign of involvement because trials studied patients with manifest disease and do not justify indefinite therapy in a healthy carrier. Symptoms, biomarkers, ECG and imaging are adapted to the variant and family. The treatment threshold should be based on organ involvement and the approved indication, not on genetic anxiety alone.

Care includes compatible exercise, nutrition, fall prevention, orthostatic management, vaccination, rehabilitation and psychological support. Frailty and sarcopenia may limit quality of life as much as cardiac parameters and require early intervention. Care beyond the precursor turns pharmacologic success into a genuinely better functional trajectory.

Prognosis has improved with early diagnosis and effective therapies but remains stage-dependent. Communicating that the disease is treatable without calling it cured supports realistic decisions about medication, heart failure and future planning. The long-term partnership is essential because ATTR-CM is increasingly a complex chronic condition to monitor, not merely a terminal diagnosis.